Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Máthé, Z; Tagkalos, E; Paul, A; Molmenti, EP; Kóbori, L; Fouzas, I; Beckebaum, S; Sotiropoulos, GC.
Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.
Transplantation. 2011; 91(5):575-582
Doi: 10.1097/TP.0b013e3182081312
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
-
Mathe Zoltan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Liver transplantation (LT) has been accepted as a treatment in selected cases of neuroendocrine tumors (NETs) with hepatic metastases.
A systematic review of the literature was conducted to evaluate long-term patient survival in the instances of LT for pancreatic NET. Univariate and multivariate regression analyses and survival analysis were performed.
Fifty-three clinical studies were screened. Data from 20 studies encompassing 89 transplanted patients were included in the study. Most primary tumors were endocrine pancreatic tumors (n=69), with gastrinomas representing the most frequent diagnosis (n=21). There were 61 functioning pancreatic NET. Simultaneous LT and pancreatic NET resections were performed in 45 instances. Cumulative 1-, 3-, and 5-year survival was 71%, 55%, and 44%, respectively, with a calculated mean survival of 54.45±6.31 months. Vasoactive intestinal peptide (VIPomas) had the best overall survival. Recurrence-free survival at 1, 3, and 5 years was 84%, 47%, and 47%, respectively. Recipient age more than or equal to 55 years (P=0.0242) and simultaneous LT-pancreatic resection (P=0.0132) were found to be significant predictors of worse survival by both univariate and multivariate Cox proportional hazard analyses. A scoring system was developed, with prognostic points assigned as follows: age more than or equal to 55 years:age less than 55 years=1:0 points and simultaneous LT-pancreatic resection:LT alone=1:0 points. This stratification delineated three separate population samples corresponding to patients with scores of 0, 1, and 2, respectively. The calculated 5-year survival for scores 0, 1, and 2 was 61%, 40%, and 0%, respectively (P=0.0023).
Despite the limitations of this retrospective analysis, good results can be achieved even for pancreatic NET primaries if the above-proposed scoring system is applied.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adolescent -
-
Adult -
-
Carcinoma, Neuroendocrine - mortality
-
Carcinoma, Neuroendocrine - secondary
-
Carcinoma, Neuroendocrine - surgery
-
Child -
-
Female -
-
Humans -
-
Liver Neoplasms - mortality
-
Liver Neoplasms - secondary
-
Liver Neoplasms - surgery
-
Liver Transplantation -
-
Male -
-
Middle Aged -
-
Pancreatic Neoplasms - pathology
-
Prognosis -
-
Retrospective Studies -
-
Survival Analysis -
-
Young Adult -
- Find related publications in this database (Keywords)
-
Neuroendocrine tumors
-
Pancreatic malignancy
-
NET
-
Liver metastases
-
Liver transplantation
-
Extended indications
-
Scoring systems